AGÕæÈ˹ٷ½

On 5-Aug-2025 Graham Corporation (NYSE: GHM) filed a Form 8-K to furnish, not file, information under Item 2.02 (Results of Operations) and Item 7.01 (Reg FD). The filing simply notifies investors that:

• Exhibit 99.1 contains the Q1 FY-2026 press release covering results for the period ended 30-Jun-2025.
• Exhibit 99.2 provides supplemental tables on historical sales, orders and backlog, which will be posted at www.grahamcorp.com.
• The furnished material is excluded from Exchange Act §18 liability and is not incorporated into other SEC filings.

No quantitative performance metrics, earnings guidance or strategic updates are included in the 8-K itself. Additional details must be obtained from the referenced exhibits.

Dimensional Fund Advisors LP (DFA) has filed a Schedule 13G indicating that, as of 30 June 2025, it beneficially owns 1,572,330 shares of Boston Omaha Corp ("BOC"), representing 5.1 % of the company’s outstanding common stock. The institutional investor reports sole voting power over 1,540,879 shares and sole dispositive power over the full 1,572,330-share position, with no shared voting or dispositive authority.

DFA, a Delaware limited partnership and SEC-registered investment adviser, explains that the shares are held across multiple mutual funds, commingled trusts and separate accounts for which it or its subsidiaries act as adviser or sub-adviser. While DFA may exercise voting and investment discretion, it expressly disclaims beneficial ownership in excess of the requirements of Section 13(d).

Crossing the 5 % ownership threshold triggers this disclosure and signals a modest increase in institutional ownership in BOC. Because DFA is predominantly a passive, quantitative manager, the filing does not suggest an activist agenda or an intention to influence control. Nevertheless, additional institutional sponsorship can enhance liquidity, broaden research coverage and potentially support the share price through index-related demand.

Key numeric details

• Date of event: 30 June 2025
• Shares owned: 1,572,330
• Percent of class: 5.1 %
• Sole voting power: 1,540,879
• Sole dispositive power: 1,572,330

Overall, the Schedule 13G is an informative but routine ownership disclosure that underscores growing passive interest in Boston Omaha without materially altering corporate governance or near-term strategy.

Takeda Pharmaceutical Company Limited (NYSE: TAK) submitted a Form 144 notifying the SEC of a proposed discretionary sale of 6,136 American Depositary Shares (ADSs) through Interactive Brokers LLC. At the reference price implied in the filing, the transaction represents an aggregate market value of approximately US$94,617. The shares were originally acquired on 07 July 2025 via vested Restricted Stock Unit (RSU) awards granted by Takeda and are scheduled to be sold on or after 09 July 2025. The number of ADSs to be sold is immaterial relative to Takeda’s total outstanding shares of 123,490,548. No sales by this individual were reported in the prior three-month period, and the filer affirmed that no undisclosed material adverse information is known.